PAPADOPOULOS STELIOS 4

What Happened

• Stelios Papadopoulos, a director of Ovid Therapeutics, was granted a derivative award on February 26, 2026: options covering 65,000 shares. The Form 4 records the acquisition price as $0.00 (no cash paid at grant). This was a grant/award (not a purchase or sale).

Key Details

• Transaction date: 2026-02-26; Form 4 filed 2026-03-02 (filed on the required SEC deadline).
• Amount: 65,000 option shares; acquisition price reported as $0.00.
• Vesting: The option will vest in full on February 26, 2027, subject to continuous service (per footnote).
• Shares owned after transaction: Not specified in this Form 4.
• Transaction type: Reported as a derivative award (options). No immediate sale or exercise reported.

Context

• This is a standard equity compensation grant to a director. It does not represent an open-market purchase (a potentially bullish signal) nor a sale. The options vest in one year if the director remains in service; exercising and any subsequent sale would be separate, later transactions and would be reported separately.